kabutan

DAIICHI SANKYO COMPANY, LIMITED(4568) Summary

4568
TSE Prime
DAIICHI SANKYO COMPANY, LIMITED
2,916.5
JPY
-11.5
(-0.39%)
Jan 29, 1:38 pm JST
19.05
USD
Jan 28, 11:38 pm EST
Result
PTS
outside of trading hours
2,913.5
Jan 29, 1:38 pm JST
Summary Chart Historical News Financial Result
PER
18.7
PBR
3.27
Yield
2.67%
Margin Trading Ratio
13.74
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
2,880.0 JPY 18.81 USD
Previous Close Jan 28
2,928.0 JPY 19.18 USD
High Jan 29, 12:32 pm
2,927.0 JPY 19.12 USD
Low Jan 29, 9:07 am
2,843.5 JPY 18.57 USD
Volume
6,862,700
Trading Value
0.02T JPY 0.13B USD
VWAP
2891.47 JPY 18.89 USD
Minimum Trading Value
291,650 JPY 1,905 USD
Market Cap
5.52T JPY 0.04T USD
Number of Trades
12,404
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
9,153
1-Year High Apr 25, 2025
29,113
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 76,900 7,278,700 94.65
Jan 16, 2026 68,600 5,441,000 79.31
Jan 9, 2026 68,500 4,093,800 59.76
Dec 26, 2025 77,200 4,472,100 57.93
Dec 19, 2025 70,200 4,751,800 67.69
Company Profile
DAIICHI SANKYO COMPANY, LIMITED is a major pharmaceutical company in Japan, with strengths in cardiovascular and infectious diseases. The company has partnered with AstraZeneca of the UK for new cancer drugs.
Sector
Pharmaceuticals
DAIICHI SANKYO COMPANY, LIMITED primarily engages in the research, development, manufacturing, and sales of pharmaceuticals, with a broad range of operations both domestically and internationally. In Japan, the company operates through multiple subsidiaries involved in pharmaceutical manufacturing, research and development and sales of over-the-counter drugs, and vaccine research, development, and production, showcasing a diverse group of companies with varied functions. The company has partnered with AstraZeneca in the oncology field. Internationally, DAIICHI SANKYO has subsidiaries in the United States, Europe, China, Brazil, and other regions, conducting pharmaceutical research, development, manufacturing, and sales in each area. In the United States, the company has established a holding company, while in Europe, it operates through numerous group companies across various countries. DAIICHI SANKYO leverages its global network for research, development, manufacturing, and sales to enhance its competitiveness in the world market.